Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound

This study has been withdrawn prior to enrollment.
(Due to lack of funding and issues with ability to complete all procedures, it was decided that this study could not be carried out and therefore withdrawn.)
Sponsor:
Information provided by (Responsible Party):
Glenn Peters, MD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01225016
First received: October 14, 2010
Last updated: January 27, 2012
Last verified: January 2012

October 14, 2010
January 27, 2012
October 2010
December 2011   (final data collection date for primary outcome measure)
To estimate the accuracy (sensitivity and specificity) of the contrast enhanced ultrasound for characterization of thyroid nodules. [ Time Frame: 30 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01225016 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound
Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound

This study will evaluate thyroid nodules using specialized ultrasound imaging methods.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Thyroid Nodules
Drug: Definity contrast agent
Thyroid ultrasound using contrast agent
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 1. Patients diagnosed with a thyroid nodule 2. Age greater than or equal to 19 years of age 3. Patients must sign informed consent

Exclusion Criteria:

  • 1. Women who are pregnant or nursing 2. Patients with pulmonary hypertension, unstable cardiopulmonary condition,or right to left shunt 3. Hypersensitivity to perfluten 4. Psychological condition that renders the patient unable to understand the informed consent
Both
19 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01225016
UAB 1007
Yes
Glenn Peters, MD, University of Alabama at Birmingham
University of Alabama at Birmingham
Not Provided
Principal Investigator: Glenn E Peters, MD University of Alabama at Birmingham
University of Alabama at Birmingham
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP